Literature DB >> 22767268

Oral doxycycline for non-systemic urinary tract infections (UTIs) due to P. aeruginosa and other Gram negative uropathogens.

B A Cunha.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22767268     DOI： 10.1007/s10096-012-1680-0

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  20 in total

1.  Oral therapy of catheter-associated bacteriuria (CAB) in the era of antibiotic resistance: nitrofurantoin revisited.

Authors:  Burke A Cunha; Paul Schoch; Jean E Hage
Journal:  J Chemother       Date:  2012-04       Impact factor: 1.714

2.  Falsely high antibiotic resistance in community-acquired E. coli UTIs requiring hospitalization.

Authors:  Naveed S Hamid; Burke A Cunha; Natalie C Klein
Journal:  Mayo Clin Proc       Date:  2005-06       Impact factor: 7.616

Review 3.  Problems arising in antimicrobial therapy due to false susceptibility testing.

Authors:  B A Cunha
Journal:  J Chemother       Date:  1997-05       Impact factor: 1.714

Review 4.  The revival of fosfomycin.

Authors:  Argyris S Michalopoulos; Ioannis G Livaditis; Vassilios Gougoutas
Journal:  Int J Infect Dis       Date:  2011-09-25       Impact factor: 3.623

5.  Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections.

Authors:  T A Stamey; W R Fair; M M Timothy; M A Millar; G Mihara; Y C Lowery
Journal:  N Engl J Med       Date:  1974-11-28       Impact factor: 91.245

6.  Gram-negative urinary infection treated with oral penicillin G.

Authors:  J Hulbert
Journal:  Lancet       Date:  1972-12-09       Impact factor: 79.321

7.  Clinical relevance of laboratory-reported antibiotic resistance in acute uncomplicated urinary tract infection in primary care.

Authors:  C A M McNulty; J Richards; D M Livermore; P Little; A Charlett; E Freeman; I Harvey; M Thomas
Journal:  J Antimicrob Chemother       Date:  2006-09-23       Impact factor: 5.790

8.  Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli.

Authors:  Simon Auer; Alexandra Wojna; Markus Hell
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

9.  Effectiveness of achievable urinary concentrations of tetracyclines against "tetracycline-resistant" pathogenic bacteria.

Authors:  D M Musher; J N Minuth; S B Thorsteinsson; T Holmes
Journal:  J Infect Dis       Date:  1975-05       Impact factor: 5.226

10.  The treatment of infection stones with penicillin.

Authors:  R M Feit; W R Fair
Journal:  J Urol       Date:  1979-11       Impact factor: 7.450
View more
  7 in total

1.  An infectious disease and pharmacokinetic perspective on oral antibiotic treatment of uncomplicated urinary tract infections due to multidrug-resistant Gram-negative uropathogens: the importance of urinary antibiotic concentrations and urinary pH.

Authors:  B A Cunha
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-09       Impact factor: 3.267

2.  Does a learned journal require regular re-vamping?

Authors:  A van Belkum
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08       Impact factor: 3.267

Review 3.  Similarities and differences between doxycycline and minocycline: clinical and antimicrobial stewardship considerations.

Authors:  B A Cunha; J Baron; C B Cunha
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-08-17       Impact factor: 3.267

Review 4.  Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review.

Authors:  Andrew Chou; Elwyn Welch; Andrew Hunter; Barbara W Trautner
Journal:  Drugs       Date:  2022-03-14       Impact factor: 11.431

Review 5.  Urinary Tract Infection and Asymptomatic Bacteriuria in Older Adults.

Authors:  Nicolas W Cortes-Penfield; Barbara W Trautner; Robin L P Jump
Journal:  Infect Dis Clin North Am       Date:  2017-12       Impact factor: 5.982

6.  In vitro activity of ceftazidime-avibactam, ceftolozane-tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).

Authors:  Shio-Shin Jean; Min-Chi Lu; Zhi-Yuan Shi; Shu-Hui Tseng; Ting-Shu Wu; Po-Liang Lu; Pei-Lan Shao; Wen-Chien Ko; Fu-Der Wang; Po-Ren Hsueh
Journal:  Infect Drug Resist       Date:  2018-10-26       Impact factor: 4.003

7.  Antimicrobial stewardship programs (ASPs): the devil is in the details.

Authors:  Cheston B Cunha; Christy A Varughese; Eleftherios Mylonakis
Journal:  Virulence       Date:  2013-02-04       Impact factor: 5.882
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.